---
title: "Tianjin Development's subsidiary Lishengpharma A's annual net profit increased by 125.6% to 416 million RMB, with a dividend of 60 cents RMB"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280388973.md"
description: "Tianjin Development's indirectly non-wholly-owned subsidiary Lishengpharma announced its full-year results for the year ended last December, with a revenue of RMB 1.392 billion, an increase of 4.2% year-on-year. The net profit was RMB 416 million, an increase of 125.6% year-on-year; earnings per share were RMB 1.62. A cash dividend of RMB 6.00 will be distributed for every 10 shares"
datetime: "2026-03-25T00:25:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280388973.md)
  - [en](https://longbridge.com/en/news/280388973.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280388973.md)
---

# Tianjin Development's subsidiary Lishengpharma A's annual net profit increased by 125.6% to 416 million RMB, with a dividend of 60 cents RMB

Tianjin Development (00882.HK) indirectly non-wholly-owned subsidiary Lishengpharma (002393.SZ) announced its full-year results for the year ended last December, with a revenue of RMB 1.392 billion, an increase of 4.2% year-on-year. The net profit was RMB 416 million, an increase of 125.6% year-on-year; earnings per share were RMB 1.62. A cash dividend of RMB 6.00 will be distributed for every 10 shares

### Related Stocks

- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [00882.HK](https://longbridge.com/en/quote/00882.HK.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [002393.CN](https://longbridge.com/en/quote/002393.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)

## Related News & Research

- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md)
- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds](https://longbridge.com/en/news/286487023.md)